Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.

Zeidan A, Bolaños-Meade J, Kasamon Y, Aoki J, Borowitz M, Swinnen L, Symons H, Luznik L, Fuchs E, Jones R, Ambinder R.

Leuk Lymphoma. 2013 Mar;54(3):655-7. doi: 10.3109/10428194.2012.717082. Epub 2012 Aug 27. No abstract available.

PMID:
22845310
2.

Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.

Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ.

Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.

PMID:
21715313
3.

Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.

Llano OG, Perez JC, Rodriguez OC, Guerra CM, Aguirre HG, Garza JL, Rodriguez-Romo L, Almaguer DG.

Pediatr Hematol Oncol. 2008 Jan-Feb;25(1):39-47. doi: 10.1080/08880010701773621.

PMID:
18231953
4.

Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.

Ikegame K, Yoshihara S, Taniguchi Y, Kaida K, Inoue T, Okada M, Taniguchi K, Hasei H, Tamaki H, Fujioka T, Kato R, Soma T, Ogawa H.

Exp Hematol. 2011 Aug;39(8):880-90. doi: 10.1016/j.exphem.2011.05.007. Epub 2011 May 27.

PMID:
21689724
5.

Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.

Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D.

Hematology. 2007 Jun;12(3):193-7.

PMID:
17558694
6.
7.

Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.

Urban C, Benesch M, Sykora KW, Schwinger W, Lackner H.

Bone Marrow Transplant. 2005 Mar;35(6):591-4.

PMID:
15665850
8.

Experts' considerations on HLA-haploidentical stem cell transplantation.

Patriarca F, Luznik L, Medeot M, Zecca M, Bacigalupo A, Di Bartolomeo P, Arcese W, Corradini P, Ciceri F, Vago L, Kanakry CG, Fleischhauer K, Martelli MF, Bosi A, Rambaldi A, Cesaro S, Russo D, Fanin R.

Eur J Haematol. 2014 Sep;93(3):187-97. doi: 10.1111/ejh.12322. Epub 2014 Apr 26.

PMID:
24660868
9.

Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B, Devereux S, Duarte RF, Pagliuca A, Mufti GJ.

Br J Haematol. 2006 Oct;135(2):201-9. Epub 2006 Aug 25.

PMID:
16939494
10.

Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.

Novitzky N, Thomas V, du Toit C, McDonald A.

Bone Marrow Transplant. 2009 May;43(10):779-85. doi: 10.1038/bmt.2008.390. Epub 2008 Dec 15.

PMID:
19079315
11.

Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.

Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.

Biol Blood Marrow Transplant. 2010 Jun;16(6):818-23. doi: 10.1016/j.bbmt.2010.01.002. Epub 2010 Jan 14.

PMID:
20079864
12.

In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, Kondo Y, Nakao S, Nagafuji K, Miyamoto T, Kurokawa M, Okoshi Y, Chiba S, Ohashi Y, Takaue Y, Taniguchi S.

Am J Hematol. 2013 Apr;88(4):294-300. doi: 10.1002/ajh.23392. Epub 2013 Feb 28.

PMID:
23450467
13.

HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.

Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G, Perotti C, Corbella F, Brescia L, Locatelli F.

Biol Blood Marrow Transplant. 2014 Apr;20(4):571-6. doi: 10.1016/j.bbmt.2014.01.015. Epub 2014 Jan 22.

PMID:
24462983
14.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.

PMID:
17869547
15.

[Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature].

Xie XS, Wan DM, Sun H.

Zhonghua Zhong Liu Za Zhi. 2010 Aug;32(8):636-7. Review. Chinese. No abstract available.

PMID:
21122422
16.

Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.

de la Fuente J, Reiss S, McCloy M, Vulliamy T, Roberts IA, Rahemtulla A, Dokal I.

Bone Marrow Transplant. 2003 Oct;32(7):653-6. Erratum in: Bone Marrow Transplant. 2004 Jul;34(1):95.

PMID:
13130311
17.

[Haploidentical 2- or 3-antigen-mismatched hematopoietic stem cell transplantation using in vivo Campath-1H].

Kanda Y.

Rinsho Ketsueki. 2006 Jul;47(7):607-17. Review. Japanese. No abstract available.

PMID:
16910570
18.

[Conditioning regimen containing fludarabine instead of cyclophosphamide for haploidentical hematopoietic stem cell transplantation].

Chen HR, He XP, Si YJ, Yang K, Hu B, DU ZL, Zhang XM, Zhang CC.

Zhonghua Xue Ye Xue Za Zhi. 2009 Aug;30(8):514-8. Chinese.

PMID:
19954636
19.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

PMID:
25865646
20.

CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.

Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK.

Bone Marrow Transplant. 2005 Jun;35(12):1127-32.

PMID:
15834432

Supplemental Content

Support Center